INOZYME PHARMA, INC. Reports Financial Results for Q2 2023

INOZYME PHARMA, INC. (INZY), a biopharmaceutical company focused on the development of innovative treatments for rare genetic disorders, announced its financial results for the second quarter of 2023. The company reported a narrowing net loss and an increase in revenue compared to the same period last year.

Net Income/Loss

INOZYME PHARMA reported a net loss of $15.6 million for the second quarter of 2023, compared to a net loss of $15.3 million for the same period in 2022. The decrease in net loss reflects the company's ongoing efforts to manage its operating expenses and optimize its research and development activities.

Revenue